This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

The main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA).PRIMARY OBJECTIVES:To evaluate the efficacy of Lu AF82422 on clinical progression in participants with MSASECONDARY OBJECTIVES:To evaluate the efficacy of Lu AF82422 on:  global clinical impression, severity of illness  global disability  functionality  disease milestones  health-related quality of life  overall survivalTo evaluate clinical meaningfulness of Lu AF82422To evaluate the efficacy of Lu AF82422 on disease progression, as measured by brain MRITo determine the population pharmacokinetic parameters of Lu AF82422To evaluate the safety and tolerability of Lu AF82422 in participants with MSA during the placebo-controlled period and OLE periodTo evaluate the immunogenicity of Lu AF82422THIS STUDY IS ENROLLING BY INVITATION ONLY

The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to pilot a multifaceted intervention for at-risk emergency department patients (i.e. those with an elevated BMI and at least one additional metabolic syndrome risk factor) to establish feasibility. Our composite intervention will include an educational video outlining the adverse effects of metabolic syndrome and the benefits of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating, periodic text message reminders to encourage activity, and a referral to outpatient follow-up. We plan to track physical activity (including number of steps and minutes spent active) using the Fitbit device with the goal of better understanding how to motivate patients to increase walking behavior.THIS STUDY IS ENROLLING BY INVITATION ONLY - Patients presenting to the Eskenazi Health Emergency Department will be screened via real-time surveillance of the tracking board for eligibility. Patients that meet study criteria based on medical record review will be approached in-person for study enrollment, consent, baseline intervention during their clinical ED visit.